The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. by Mondanelli, Giada et al.
The immune regulation in cancer by the amino acid
metabolizing enzymes ARG and IDO
Giada Mondanelli1,*, Stefano Ugel2,*, Ursula Grohmann1,** and
Vincenzo Bronte2,**
Available online at www.sciencedirect.com
ScienceDirectSome enzymes degrading amino acids have evolved in
mammals to dampen immune responses and maintain
peripheral tolerance. The enzymes metabolizing L-arginine and
L-tryptophan are particularly powerful, contributing to restrain
immunity towards fetal tissues and establish neonatal
tolerance. Solid tumors can hijack these formidable pathways
to construct a microenvironment highly unfavorable to anti-
tumor T lymphocytes able to recognize them, one of
mechanisms for their immune evasion. In this review, we
analyze emerging concepts in the cross-talk between cells
expressing these enzymes, their immune regulatory functions
and pharmacological approaches that can target them to
enhance cancer immunotherapy.
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Introduction
Cancer immunotherapy has profoundly changed the out-
come of cancer patients. However, recent evidence indi-
cates that immunotherapy, including novel antibodies
blocking T cell checkpoints, is successful in a proportion
of patients. For example, the efficacy of Nivolumab, an
anti-PD1 monoclonal antibody that has been approved by
the Food and Drug Administration (FDA) for the treat-
ment of patients with advanced non-small cell lung
cancer, is far from optimal with a response rate of 15–
20% [1]. Therefore, there is an urgent need to identify
and remove tumor microenvironment cues that limit TCurrent Opinion in Pharmacology 2017, 35:30–39 cell functionality. One emerging strategy, which is being
tested in clinical trials (Tables 1–3), is based on the
pharmacological modulation of enzymes that degrade
amino acids.
Arginase in the tumor microenvironment
L-arginine is a non-essential amino acid that is involved in
the synthesis of many metabolites, such as nitric oxide
(NO) and polyamines (putrescine, spermidine, sper-
mine), as well as in protein post-translational modification
and immune regulation [2]. Therefore, L-arginine avail-
ability can intervene in different aspects of reprogram-
ming energy metabolism, recently identified as a new
hallmark of cancer [3]. High levels of intracellular L-
arginine not only favor the T cell fitness, activation,
differentiation and function by neutralizing the Warburg
effect [4] through the shift from glycolysis to oxidative
phosphorylation (OXPHOS), but also support the gener-
ation of central memory-like T (TCM) cells with superior
survival capacity and anti-tumor activity [5]. On the
contrary, L-arginine depletion profoundly suppresses T
cell immune responses by decreasing cyclin D mRNA
translation and blocking the activity of several cyclin-
dependent kinases, which are essential for the cell cycle
advancement from G0/G1 to S-phase [6] as well as pro-
moting T-cell anergy/paralysis via the down regulation of
the T cell receptor (TCR) z chain [7]. Arginase (ARG) is
the key enzyme that catalyzes L-arginine towards the
downstream byproducts L-ornithine and urea. In mam-
mals, two distinct ARG enzymes are present: ARG1 and
ARG2. These two enzymes share 58% homology and
catalyze the same biochemical reaction but they are
distinguished by different cellular expression, molecular
regulation and subcellular localization [8]. ARG1 is a
constitutive cytosolic enzyme mainly expressed in the
liver [9], erythrocytes [10] and human tertiary neutrophil
granules where it is inactive but becomes active after its
extracellular release [11,12]. In mouse, ARG1 is also
present in other immune cells such as mouse lung-resi-
dent group 2 innate lymphoid cells [13], macrophages and
dendritic cells (DCs) [14]. In association with the gamma
amino butyric acid signaling pathway, ARG1 drives both
neural maturity and neuroblastoma development [15].
ARG2 is a mitochondrial enzyme preferentially expressed
in the lactating mammary glands, kidney and prostate [9].
It is activated also in the CD71-expressing erythroid cell
subset in both neonatal mice and human cord blood,
conferring them immunosuppressive and tolerogenic
function post-birth [16].www.sciencedirect.com
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Table 1
ARG and IDO1 inhibitors: from bench to beside
Enzyme inhibitor Chemical structure Chemical formula Cas-number Validation of immunomodulation effect
NG-hydroxy-L-arginine
[NOHA]
(ARG Inhibitor)
C6H14N4O3  C2H4O2 53598-01-9  In human prostate carcinoma organ cultures, NOHA rescued the T cell
proliferation [19].
 No clinical trials on cancer patients.
Nv-hydroxy-nor-Arginine
[nor-NOHA]
(ARG Inhibitor)
C6H14N4O3  C2H4O2 1140844-63-8  In vitro nor-NOHA blocked suppressive activity of MDSCs.
 In vivo nor-NOHA administration in tumor-bearing mice promoted a
dose-dependent T cell-mediated anti-tumor response [53].
 Nor-NOHA was tested in a phase I clinical trial (NCT02009527) to
evaluate the effect of arginase inhibition in ischemia-reperfusion injury; as
well as in phase I and II clinical trial (NCT02687152) to test the therapeutic
effect on controlling microvascular endothelial dysfunction in patients
affected by type 2 diabetes.
 No clinical trials on cancer patients.
S-(2-Boronoe
thyl)-L-cysteine hydrochloride
[BEC hydrochloride]
(ARG Inhibitor)
C5H12BNO4S  XHCL 63107-40-4  In vitro BEC hydrochloride decreased arginase activity [54].
 The inhibitor administration in association with immunotherapy
(adoptive cell transfer) limited cancer progression in tumor-bearing mice
[54].
 No clinical trials on cancer patients.
CB-1158
(ARG Inhibitor)
C18H27BCl2N2O4 1345810-21-0  CB-1158 in combination with standard treatment promoted a better
control of tumor growth in preclinical tumor settings [57].
 CB-1158 is currently in a Phase I clinical trial in solid tumor patients.
Phosphodiesterase
5 inhibitors [Tadalafil,
Sildenafil]
(ARG transcription Inhibitor)
C22H19N3O4 171596-29-5  Inhibitor administration in tumor-bearing mice blocked MDSC function
favoring a spontaneous anti-tumor response [56].
 Inhibitor administration in tumor-bearing mice increased the
therapeutic impact of adoptive T cell therapy [56].
 Inhibitor treatment of peripheral blood mononuclear cells isolated from
multiple myeloma patients resulted in increased T cell proliferation in
vitro.
 Tadalafil is currently in Phase II clinical trial in tumor patients.
NCX 4016
[Nitroaspirin]
(ARG transcription Inhibitor)
C16H13NO7 175033-36-0  In vivo administration of nitroaspirin in tumor-bearing mice blocked
MDSC function restoring immunotherapy efficacy [55].
 NCX4016 was tested in a phase II clinical trial (NCT01256775) to
improve the functional capacity of peripheral arterial disease patients
affecting atherosclerosis progression; as well as in phase I clinical trial
(NCT00331786) to prevent colorectal cancer.
AT38
([3-(aminocarbonyl) furoxan-
4-yl] methyl salicylate)
(ARG transcription Inhibitor)
C11H9N3O6 148:553081  In vivo administration of AT38 to tumor-bearing mice controls the
generation of reactive nitrogen species in tumor microenvironment
favoring a massive T cell infiltration [27].
 No clinical trials on cancer patients.
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Table 1 (Continued )
Enzyme inhibitor Chemical structure Chemical formula Cas-number Validation of immunomodulation effect
INCB024360
[Epacadostat]
(IDO inhibitor)
C11H13BrFN7O4S 1204669-58-8  INCB024360 promoted the proliferation of several immune cells,
including NK cells, and T-lymphocytes, as well as the production of IFN-g
in tumor-bearing mice.
 NCB024360 administration in tumor-bearing mice induced a
contraction of tumor-associated Tregs [61].
 INCB024360 is currently in Phase I, II and III clinical trials in tumor
patients.
NLG8189
[Indoximod,1-methyl-D-
tryptophan]
(IDO inhibitor)
C12H14N2O2 110117-83-4 NLG8189 administration in tumor-bearing mice limited the expansion of
tumor-associated Tregs [59].
 NLG8189 enhanced the adaptive immunologic response induced by
DC vaccine in preclinical models [60].
 INCB024360 is currently in Phase I and II clinical trials in tumor patients.
GDC-0919
(IDO inhibitor)
C18H22N2O 1402836-58-1  GDC-0919 restored the physiological tryptophan levels that favor, NK
cell and T lymphocyte proliferation and induces a specific cytotoxic
immune response against IDO1-expressing tumor cells.
 GDC-0919 is currently in a Phase I clinical trial in solid tumor patients.
PF-06840003
(IDO inhibitor)
C12H9FN2O2 198474-05-4  PF-06840003 reversed IDO1-associated T-cell anergy in vitro.
 PF-06840003 inhibited tumor growth in multiple preclinical syngeneic
mouse tumor models in combination with immune checkpoint inhibitors
[64].
PF-06840003 is currently in a Phase I clinical trial in solid tumor patients.
Table 2
Clinical trials involving ARG inhibitor (source: https://clinicaltrials.gov/)
Enzyme inhibitor Trial number Phase Cancer Status Combined treatment Primary outcome
CB-1158
(ARG inhibitor)
NCT02903914 I Advanced and
metastatic solid tumors
Recruiting Nivolumab  Safety and tolerability
NCX 4016
(ARG transcription inhibitor)
NCT00331786 I Colorectal Cancer Completed  Effects of NCX 4016 on aberrant cryptic foci
multiplicity after the second dose at 6 months
Tadalafil (ARG transcription
inhibitor)
NCT01858558 I Multiple Myeloma Recruiting Prevnar vaccine,
Lenalidomide
 Progression free survival
NCT01374217 I Multiple Myeloma Terminated Lenalidomide
dexamethasone
 Anti-tumor efficacy
NCT02544880 I, II Head and Neck Cancer Recruiting Anti-Tumor MUC1 Vaccine  Safety and tolerability
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Table 3
Clinical trials involving IDO inhibitors (source: https://clinicaltrials.gov/)
Enzyme inhibitor Trial number Phase Cancer Status Combined treatment Primary outcome
INCB024360
(Epacadostat)
NCT01685255 II Reproductive tract tumors Completed Compared to Tamoxifen Progression free survival
NCT02166905 I, II Reproductive tract tumors Recruiting DEC-205/NY-ESO-1
Fusion protein
CDX-1401
Maximum tolerated dose (I) and progression free survival (II).
NCT02118285 I Reproductive tract tumors Recruitment
suspended,
pending
amendment
NK cells, IL-2 Maximum tolerated dose
NCT01822691 II Myelodysplastic syndromes Completed Overall response rate
NCT02042430 Pilot study Reproductive tract tumors Ongoing Number of participants with an increase in CD8+ T cells and
its correlation with IDO expression.
NCT01961115 II Melanoma Recruiting Multipeptide Melanoma
Vaccine (MELITAC 12.1)
Changes in the concentration and number of CD8+ TILs
NCT02785250 I Reproductive tract tumors Recruiting DPX-Survivac,
cyclophosphamide
Safety, cell mediated immunity and evaluation of treatment-
induced changes in TILs
NCT02575807 I, II Reproductive tract tumors Recruiting CRS-207 Number of patients reporting treatment-related adverse
events; ratio of CD8/Treg TILs; plasma L-Kyn/L-Trp ratio
NCT01604889 I, II Metastatic melanoma Ongoing Ipilimumab Safety and tolerability, overall survival.
NCT02959437 I, II Advanced solid tumors Recruiting Azacitidine
Pembrolizumab
Frequency, duration, and severity of adverse events;
objective response rate
NCT02559492 I Advanced solid tumors Recruiting JAK inhibitor
(INCB039110)
PI3K-delta inhibitor
(INCB050465)
Dose-limiting toxicities
NCT01195311 I Advanced malignancies Completed Safety and tolerability.
NCT03006302 II Metastatic pancreatic
adenocarcinoma
Not yet recruiting Pembrolizumab,
cyclophosphamide,
CRS-207, GVAX
Recommended dose of Epacadostat and 6 month survival.
NCT02298153 I Non-small Cell Lung Cancer
Urothelial Carcinoma
Recruiting Atezolizumab Incidence of adverse events and incidence of dose-limiting
toxicities
NCT02318277 I, II Selected advanced
solid tumors
Recruiting Durvalumab (MEDI4736) Dose-limiting toxicities and frequency, duration, and severity
of adverse events; objective response rate
NCT02178722 I, II Selected solid tumors Recruiting Pembrolizumab Dose limiting toxicities and objective response rate
NCT02327078 I, II Selected solid tumors Recruiting Nivolumab Safety and tolerability (I) and overall objective response rate,
overall survival (II)
NCT02862457 I Advanced solid tumors Recruiting Pembrolizumab Dose-limiting toxicities and adverse events
NCT02752074 III Melanoma Recruiting Pembrolizumab Progression-free and overall survival
NCT01982487 I, II Reproductive tract tumors Withdrawn ALVAC(2)-NY-ESO-1 (M)/
TRICOM vaccine
Maximum tolerated dose of IDO1 inhibitor
NCT03085914 I, II Advanced and metastatic
solid tumors
Not yet recruiting Nivolumab,
Pembrolizumab and
chemotherapy
Safety and tolerability (I) and overall objective response rate,
overall survival (II)
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Table 3 (Continued )
Enzyme inhibitor Trial number Phase Cancer Status Combined treatment Primary outcome
1-methyl-D-tryptophan
(Indoximod)
NCT02460367 I, II Non-small Cell Lung Cancer Recruiting Docetaxel
Tergenpumatucel-L
Limiting Toxicity and progression free survival
NCT02502708 I Malignant brain tumor Recruiting Temozolomide,
radiation
Limiting Toxicity and objective response rate
NCT01792050 II Metastatic breast cancer Ongoing Docetaxel, Paclitaxel Progression free survival
NCT02073123 I, II Metastatic melanoma Recruiting Ipilimumab, Nivolumab,
Pembrolizumab
Safety and tolerability (I), overall response rate (II)
NCT02052648 I, II Malignant brain tumor Recruiting Temozolomide
Bevacizumab
Radiation
Determine phase 2 dosing (I); efficacy as 6 month
progression-free survival (II)
NCT02077881 I, II Metastatic pancreatic
cancer
Recruiting Gemcitabine
Paclitaxel
Dosing, limiting toxicity, survival
NCT00567931 I Adult solid tumor Completed Incidence of adverse events and definition of maximum
tolerated dose
NCT02835729 I, II Acute myeloid leukemia Recruiting Cytarabine, Idarubicin Safety and tolerability (I), overall survival (II)
NCT00739609 I Selected solid tumors Terminated Safety and efficacy of administration of D-1MT
NCT01560923 II Metastatic prostate cancer Ongoing Sipuleucel-T Immune response to Sipuleucel-T
NCT01042535 I, II Metastatic breast cancer Ongoing Adenovirus-p53
transduced dendritic cell
vaccine
Maximum tolerated dose and number of participants with
stable disease in response to study therapy
NCT01302821 Pilot study Breast cancer Withdrawn Adenovirus-p53
transduced dendritic cell
vaccine
Occurrence of Detected Changes in Regions of Interest
NCT01191216 I Adult solid tumor Completed Docetaxel Maximum tolerated dose
GDC-0919
(IDO inhibitor)
NCT02048709 I Solid tumor Completed Limiting Toxicity
NCT02471846 I Metastatic incurable
solid tumor
Recruiting Atezolizumab Dose-limiting toxicities and adverse events
PF-06840003
(IDO inhibitor)
NCT02764151 I Oligodendroglioma
Astrocytoma
Malignant Glioma
Recruiting Dose-limiting toxicities and disease control
IDO peptide
vaccine
NCT03047928 I, II Metastatic melanoma Ongoing, Not
yet recruiting
Nivolumab
PD-L1/IDO peptide
Safety and tolerability
NCT01219348 I Lung cancer Completed Safety and tolerability
NCT01543464 II Malignant melanoma Terminated GM-CSF, Imiquimod and
Temozolomide
Clinical benefit rate
NCT02077114 I Malignant melanoma
with metastasis
Completed Ipilimumab, Vemurafenib Safety and tolerability
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Arginine and trypthophan metabolism in cancer Mondanelli et al. 35In many cancers, such as breast [17], gastric [18], prostate
[19], neuroblastoma [20] and acute myeloid leukemia [21]
the ARG activity in tumor environments is enhanced,
generating an inhospitable milieu for T cell fitness. Local
immune suppression can be driven by ARG2-expressing
cancer-associated fibroblasts [22] but, overall, the most
common observation is the expansion and accumulation
of ARG1-producing tumor-infiltrating myeloid cells, such
as tumor-associated macrophages (TAMs), myeloid-
derived suppressor cells (MDSCs) and DCs. In these
cells, ARG1 is turned on in response to several tumor-
derived soluble factors and metabolites, such as interleu-
kin (IL)-4, IL-13, IL-6, macrophage and granulocyte
macrophage colony-stimulating factor (M-CSF and
GM-CSF), transforming-growth factor (TGF)-b, lactate
and cyclic adenosine monophosphate (cAMP), but also by
molecular pathways controlled by the hypoxia inducible
factor-1 alpha (HIF-1a) (reviewed in Refs. [23,24]).
The ARG1 expression is finely tuned by cell-specific
transcription factors and nuclear receptors. Indeed, the
peroxisome proliferator-activated receptors (PPARg and
PPARd), members of signal transducer and activator of
transcription family (STAT6, STAT3), the CCAAT-
enhancer-binding proteins (c/EBPb) and the interferon
regulator factor 8 (IRF8), as well as CHOP, PU.1, Krup-
pel-like factor 4 (KLF4) and activator-protein 1 (AP-1)
transcriptional factors promote ARG1 expression binding
directly to distinct region of the ARG1 gene promoter
(reviewed in Refs. [23,25]).
Since many of these tumor-associated myeloid cells also
trigger nitric oxide synthase enzymes (iNOS or NOS2),
which normally produce NO from L-arginine and oxygen,
the low level of L-arginine induced by the forced ARG1
activity promotes NOS uncoupling and consequent pro-
duction of superoxide anion (O2
). Under pathological
contexts, such as cancer, NO and O2
 levels raise and
combine to generate a variety of reactive nitrogen species
(RNS) such as peroxinitrites (ONOO), which compro-
mise both the activity and migration of T cells in tumor
site [26–28].
However, we recently demonstrated that ARG1 has a
hierarchical negative role when compared to NOS2 in
creating a tumor-derived immunosuppressive environ-
ment since NOS2-expressing myeloid cells (such as
TipDCs) can mediate a strong anti-tumor effect collabo-
rating with adoptively transferred T cells in tumor
debulking [29]. It is still not clear whether ARG1
activity in patients negatively affects the anti-tumor
immune response. However, the prompt reduction in
ARG1+ myeloid cells in melanoma patients treated with
Ipilimumab suggests that the anti-tumor activity of this
checkpoint inhibitor might involve, in part, ARG1 sys-
temic modulation [30]. It remains to be determined
whether the drop in ARG1+ myeloid cells is predictivewww.sciencedirect.com of a better clinical outcome following different immuno-
therapy approaches.
IDO1: not just catabolism of tryptophan
An important mechanism of immune resistance in tumors
involves the metabolism of L-tryptophan (Trp), the rarest
essential amino acid found in food. More than 90% of Trp
entered with diet is catabolized via the kynurenine path-
way, a cascade of enzymatic steps that produces several
biologically active molecules, collectively known as
kynurenines, before finally producing the essential pyri-
dine nucleotide, NAD+ (nicotinamide adenine dinucleo-
tide) [2,31–33]. NAD+ is a fundamental coenzyme for
various physiological processes including DNA repair,
cell growth and energy metabolism [34]. The most inter-
esting enzymes along the pathway are indoleamine 2,3-
dioxygenase 1 (IDO1) and tryptophan dioxygenase
(TDO), which mediate the first rate-limiting step by
promoting the oxidative breakdown of the Trp indole
group. Though catalyzing the same enzymatic reaction,
IDO1 and TDO show quite distinct structural features. In
fact, the definition of the crystal structure of human
IDO1, a monomeric and cytoplasmic enzyme, has
revealed a folding into a catalytic large C-terminal
domain, a noncatalytic small N-terminal domain, and a
long loop connecting the two domains. In contrast, TDO
has a homotetrameric structure, in which each monomer,
when aligned to IDO1, appears to contain the large
catalytic but not the small domain. IDO1 and TDO
are also endowed with a distinct tissue expression, being
IDO1 highly inducible in immune cells and TDO con-
stitutive and mainly confined in the liver. Nevertheless,
both of them have been found to be also expressed in
several types of tumors and to play a major role in
dampening anti-tumor immunity. Although indicated
for years as the third immunoregulatory Trp catabolizing
enzyme, the IDO1 paralogue IDO2 seems rather to be
pro-inflammatory and to catalyze a distinct reaction [35].
IDO1- and TDO-mediated immunoregulatory effects
involve Trp deprivation but also production of kynure-
nines. As a result, the catalytic activity of these enzymes
mediates multiple effects on T lymphocytes, including
inhibition of proliferation, apoptosis, and differentiation
towards a regulatory phenotype [33]. Whereas Trp depri-
vation mainly downregulates the expression of CD3z in T
lymphocytes similarly to ARG1 [36], L-kynurenine, the
product of both IDO1 and TDO, is an endogenous
agonist of the arylhydrocarbon receptor (AhR), a
ligand-activated transcription factor in both T cells and
DCs, the most professional antigen presenting cells. As a
result, AhR activation promotes conversion of effector T
lymphocytes into regulatory T (Treg) cells and upregu-
lates IDO1 expression in DCs, further amplifying immu-
noregulatory effects and blocking anti-tumor immunity [
37–39].Current Opinion in Pharmacology 2017, 35:30–39
36 CancerFew years ago, a completely new perspective was pro-
vided for IDO1 but not TDO or IDO2 biology [39,40].
IDO1 does not merely degrade Trp and produce kynur-
enines, but it also acts as a signal-transducing molecule,
an effect that leads to long-term expression of IDO1 in
DCs and immune tolerance in vivo and is mostly inde-
pendent of IDO1’s enzymic activity. IDO1’s signaling
function relies on the presence of two immunoreceptor
tyrosine-based inhibitory motifs (ITIMs) in the noncata-
lytic, small domain of IDO1. Interestingly, IDO2 contains
only one functional ITIM and does not transduce signals.
IDO1 nonenzymatic activity is triggered in DCs by the
immunosuppressive cytokine TGF-b, which promotes
IDO1 phosphorylation by kinases of the Src family and
consequent direct interaction of the phosphorylated
enzyme with tyrosine phosphatases SHP-1 and SHP-2.
In contrast, pro-inflammatory IL-6 shortens IDO1’s half-
life driving direct interaction with suppressor of cytokine
signalling 3 (SOCS3) [41,42]. In fact, SOCS3, upon
binding the same phosphorylated ITIMs bindable by
SHPs, leads to ubiquitination and subsequent proteaso-
mal degradation of IDO1 by recruiting members of the
E3 ubiquitin ligase complex. Thus, depending on envi-
ronmental conditions, IDO1 can bind distinct molecular
partners, which can either prolong IDO1’s half-life and
promote long-term immunoregulatory effects or reduce
IDO1’s half-life and favor inflammatory responses. Very
recently, by means of IDO1 mutants, we were able to
ascertain that each phosphorylated IDO1 ITIM would
favor binding of SHPs (ITIM1) or SOCS3 (ITIM2) [43].
As a whole, these observations would indicate that the
noncatalytic portion of IDO1 is a regulatory domain,
which can act either positively or negatively for IDO1
expression depending on the cellular microenvironment
and, in addition to the catalytic site, may represent a novel
drug target.
TGF-b, Arg1, and IDO1: an
immunosuppressive triad at work in
dendritic cells
As a whole, data available on IDO1 and ARG1 suggest that
the two enzymes work in different cells, either through
pathways that deplete the amino acids or via the combined
effects of immunoregulatory metabolites and signaling
activity. While IL-4 and IFN-g are the main inducers of
ARG1 [24] and IDO1 [31] in myeloid cells, respectively,
the cytokine TGF-b can affect both enzymes, although
apparently in different cell types. TGF-b is indeed able to
confer both IDO1 competence and tolerogenic activity on
otherwise immunogenic CD8 DCs [44] and enhance the
ARG1 activity in rat peritoneal macrophages [45].
Recently, we proposed a new ‘relay’ pathway in mature
conventional DCs based on the sequential actions of
TGF-b, ARG1, and IDO1 [46]. We found that TGF-bCurrent Opinion in Pharmacology 2017, 35:30–39 induces both ARG1 and IDO1 in DCs, with ARG1
being upregulated much more rapidly than IDO1. The
sequence between the two enzymes also implies the
need of ARG1 activity to increase IDO1 expression. As
opposed to IDO1, which is endowed with signaling
activity [47], ARG1 was found to affect cellular functions
through regulation of L-arginine and L-ornithine avail-
ability. L-ornithine is the substrate for both ornithine
decarboxylase (ODC) to produce polyamines, involved
in the control of inflammation, and ornithine aminotrans-
ferase (OAT) to generate proline, fundamental for the
synthesis of collagen and thus for tissue repair. As a
consequence of ARG1 activation by TGF-b, DCs start
to produce L-ornithine, which, in turn, favors the phos-
phorylation of IDO1 and the consequent activation of
long-term immunoregulatory signaling. However, this
activity is strictly dependent on the decarboxylation of
ornithine into polyamines, since it is blunted in the
presence of a pharmacological inhibitor of ODC.
Polyamines are bioactive polycations extensively studied
in tumors, where they promote cancer cell proliferation
via the activation of different kinases, such as MAPK and
Src kinase [48]. Our data thus unveiled a new role for the
polyamine spermidine that, through the activation of the
Src kinase, promotes IDO1 phosphorylation and signaling
events in DCs. This circuitry, turned on by TGF-b, can
occur not only between DCs, but also between DCs and
MDSCs. MDSCs, being an abundant source of TGF-b
and expressing high levels of ARG1, can educate DCs to
express an IDO1-dependent tolerogenic phenotype, via
the arginine metabolites (Figure 1).
The network established by TGF-b, ARG1, and IDO1
could be very important in the context of cancer. In order
to propel their progression and invasion, tumors are very
apt to co-opt metabolic and immunosuppressive net-
works, such as the one established between IDO1 and
ARG1 (Figure 1). In addition to direct amino acid degra-
dation by cancer cells themselves [49,50], tumors could
recruit immunoregulatory cells expressing ARG1 and
IDO1 and secrete immunosuppressive cytokines, such
as TGF-b and IL-10 [51,52]. Therefore, the simultaneous
inhibition of the ARG1 and IDO1 activities, and/or TGF-
b signaling, may provide a powerful strategy in tumor
immunotherapy.
Pharmacological control
The anti-tumor effect of ARG inhibitors is suggested by
in vitro and in vivo preclinical data: NG-hydroxy-L-argi-
nine [NOHA] inhibits ARG activity restores tumor-infil-
trating T lymphocyte responsiveness to stimulation in
human prostate carcinoma organ cultures [19]; Nv-
hydroxy-nor-Arginine [nor-NOHA] abrogates T cell pro-
liferative arrest, favoring the immune attack of cancer
cells [53]; analogously, the S-(2-Boronoethyl)-L-cysteine
hydrochloride [BEC hydrochloride] administration inwww.sciencedirect.com
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Figure 1
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Scheme of the relay pathway between L-arginine and L-tryptophan catabolism.
Cancer cells produce different cytokins such as IL-6, IL-4, IL-10, GM-CSF, M-CSF, TGF-b that collectively activate several arginase 1 (ARG1)-
regulating transcriptional factors on myeloid-derived suppressor cells (MDSCs). The up-regulation of ARG1 activity produces a consumption of
extracellular L-arginine (L-Arg) since it is converted into L-ornithine (L-Orn). Low levels of extracellular L-Arg blocks T cell fitness by favoring a
glycolysis metabolism. MDSCs convert L-Orn into polyamines such as putrescine (PUT), spermidine (SPD), and spermine (SPM) by the activation
of the enzyme ornithine decarboxylase (ODC). PUT, SPM and SPD can be released in the extracellular environment by MDSCs and condition
dendritic cells (DCs) to trigger IDO1. High concentrations of polyamines favor the activation of the Src kinase that promotes IDO1 phosphorylation
and SHP-related signaling events prolonging IDO1 expression and sustaining TGF-b production. This activated state is maintained by a positive
autocrine loop mediated by the release/uptake of TGF-b. After TGF-b binding to its receptor, DCs switch on the ARG1-dependent metabolism
that preserves their intracellular high concentration of both L-Orn and polyamines driving IDO1-related immunosuppression. Immunosuppressive
functions are based on either the TGF-b release that supports the clonal expansion of antigen-specific natural regulatory T (Treg) cells and
induces the conversion of naı¨ve CD4+ T cells into induced Treg cells or the catabolism of L-tryptophan (L-Trp) into L-kynurenine (L-Kyn) that blocks
T cell proliferation and sustain Treg differentiation.association with immunotherapy limits cancer progres-
sion in tumor-bearing mice [54]. The in vivo injection of
drugs with multiple actions, including ARG transcription
inhibition, such as AT38 ([3-(aminocarbonyl) furoxan-4-
yl] methyl salicylate) [27] and NCX 4016 (nitroaspirine)
[55], restores the anti-cancer immune response favoring
immunotherapy success. Finally, the administration of
phosphodiesterase 5 inhibitors, another potential ARG
transcription inhibitor, increases the therapeutic impact
of adoptive T cell therapy [56] and one of such drugs is
being tested in a phase II clinical trial.
An impact on controlling tumor progression in several
preclinical cancer settings has been recently describedwww.sciencedirect.com with a novel ARG-inhibitor, CB-1158 [57] (Table 1). A
phase I clinical trial is now investigating the safety profile
of CB-1158 in advanced solid tumors in a combination
therapy with the immune checkpoint inhibitor Nivolu-
mab (Table 2. Several compounds targeting IDO1 cata-
lytic activity have demonstrated anti-tumor effects
(Table 1). Among these, 1-methyl-DL-tryptophan (1-
MT) has been the most widely studied. 1-MT is a
tryptophan analogue with an N-methyl substitution at
the indolic ring. Biochemical and cellular assays have
revealed that 1-MT isomers have a different activity;
in particular, the S-stereoisomer (L-1MT) is more active
than the R-stereoisomer (D-1MT) [58]. However, despite
these in vitro evidences, D-1MT (indoximod) has provenCurrent Opinion in Pharmacology 2017, 35:30–39
38 Cancerto be more effective that L-1MT in delaying tumor
growth in vivo [59,60] and is actually in Phase I/II clinical
trials in combination with chemotherapeutic drugs
(Table 3). From a library of natural products, novel
modulators of IDO1 have been discovered, including
brassinin, exiguamine A, annulin B and NSC401366.
Although most of these natural compounds have been
used for lead optimization studies, none of them has
reached clinical trials. On the other hand, the screening
of synthetic small molecule libraries has led to the iden-
tification of potent and selective IDO1 ligands. One of the
most promising candidates is Epacadostat (also known as
INCB024360), a nanomolar inhibitor of IDO1 developed
by the Incyte Corporation. Epacadostat is an orally
administered, hydroxyamide small molecule inhibitor
of IDO1 that not only demonstrated an impact in restor-
ing NK and T cell function and reducing the T cell
conversion in Treg-like lymphocytes in vitro but also
suppressed in vivo kynurenine generation and tumor
growth in immunocompetent, but not immunodeficient,
mice [61]. Moreover, in association with Ipilimumab, this
oral inhibitor promotes both a favourable objective
response rate and an increase control disease rate in
patients with advanced cancer [62]. Interestingly,
CTLA-4, an inhibitory receptor expressed by T cells,
can activate a ‘reverse signalling’ via B7 molecules in DCs
and upregulate IDO1 [63], thus suggesting that Ipilimu-
mab may indirectly also inhibit the IDO1 pathway.
Recently, New Link Genetics developed the inhibitor
GDG-0919, a molecule active in nanomolar range with
good oral bioavailability. A phase I clinical trial is now
investigating the toxicity profile of this IDO1-inhibitor as
single therapy for advanced solid tumors. Finally a new
inhibitor designed by Pfizer and Iteos Therapeutic is
being tested in a phase I clinical trial [64] (Table 3).
In conclusion, achieving a better understanding of the L-
arginine and L-tryptophan metabolism in cancer, the
complexity of amino acid catabolism-sensing pathways
and immune response to tumor is warranted for providing
new strategies for cancer immunotherapy.
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